Skip to content

Research and Clinical Value of New Classification for Premature Ejaculation: Multi-Center Research

Research and Clinical Value of New Classification for Premature Ejaculation:Multi-Center Research

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02572037
Enrollment
568
Registered
2015-10-08
Start date
2015-10-31
Completion date
2017-07-30
Last updated
2019-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premature Ejaculation

Keywords

Premature ejaculation, Dapoxetine, local anaesthetics, nerve electrophysiology

Brief summary

An observational study on the effect of new classification for premature ejaculation.

Detailed description

Premature ejaculation (PE) is one of the the most common male sexual dysfunctions and it has negative impacts on people's quality of life. According to the time that PE syndromes come out, PE is clinically divided to primary PE , which appear from the first sex ,and secondary PE ,which occurred after a period of normal ejaculation. This method of classification make little sense for treatment. In 2008, PE was divided into four types: primary PE, secondary PE, natural variable PE and premature-like ejaculatory dysfunction , and different types of premature ejaculation have their corresponding treatment. Both method of classification are based on the subjective feelings of patients, then whether certain objective test can be used to help diagnosing premature ejaculation? The drug treatment of PE mainly includes local anesthetics and selective 5- serotonin reuptake inhibitor (SSRI), and the selective penile dorsal nerve block is the most used surgery. But the efficacy of dapoxetine(a new SSRI for PE) and local anesthetics is only about 60-70% and 60%, respectively, while the efficacy of surgery is not exact without a standard surgical indication. We suppose that there may be different subtypes of the nerve of patients with premature ejaculation may exist in, which corresponds to a specific treatment. In previous study, the investigators studied the somatic sensory pathway and autonomic nerve function of patients with premature ejaculation, and found that they were characterized by different neural electrophysiological characteristics. About 60% patients with primary PE show hypersensitivity of penis, and the efficacy of local anesthetics or selective penile dorsal nerve block for them reached 90%. While SSRI can reduce the excitability of the sympathetic nervous system in patients with PE, and the effect of this drug on patients with Sympathetic hyperexcitability is better than those without Sympathetic hyperexcitability. Thus doctors here have already been dividing patients who only suffer from PE(no other diseases mentioned in exclusion criteria)into 4 groups according to the results of nerve electrophysiological examination and give corresponding treatment: 1. Penile sensory hyperexcitability Group, using local anaesthetics(compound lidocaine cream)to treat; 2. Sympathetic hyperexcitability Group: using selective serotonin reuptake inhibitor(SSRI)(Dapoxetine) to treat. 3. Mixed type Group: both Penile sensory hyperexcitability and Sympathetic hyperexcitability: Combined use of two treatments above. 4. Other Group: result of nerve electrophysiological examination is normal: this group of patients will receive further examination to figure out the reason. This pattern of treatment has been used in clinical practice for years. In this research, the investigators will systemically observe the result of this classification and treatment for 12 weeks. Patients will be asked for participating in this research. The questionnaires(IELT,PEDT,PEP) can be filled in when visited or online about every 4 weeks. If he refused , he would still receive the classified treatment but not enrolled in this research. After treatment of 12 weeks, the investigators will measure the change of IELT, PEDT, PEP, nerve electrophysiological examination and CGIC, then compare the efficacy of the treatment to that has been reported before. If anyone do not want to continue the treatment, he could quit from this research. Software SPSS17.0 will be used for data analysis. The age, height, weight, quantity table, the latency and amplitude of each group will be expressed by the mean add or subtract standard deviation. Quantitative data comparison among groups was analyzed by single factor variance analysis (one-way ANOVA and LSD), comparison of rate using x2 test, comparison of before and after treatment compared with paired t test. P\<0.05 showed statistically significant difference.

Interventions

None listed

Sponsors

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

1. Male aged between 18 and 60; 2. Men in stable heterosexual, monogamous relationships \>6 months; 3. Symptom of PE: Ejaculation that always or nearly always occurs prior to or within 2 minute of vaginal penetration from the first sexual experience; the inability to delay ejaculation; and negative personal consequences, such as distress, bother, frustration, and/or the avoidance of sexual intimacy.

Exclusion criteria

1. Urinary system infection: Abnormal result of routine urine and prostatic fluid routine examination; 2. Abnormal sex hormone: Abnormal result of sex hormone examination; 3. Systemic disease: hypertension, diabetes mellitus, alcohol dependence syndrome, coronary heart disease, and Mental disorder; 4. Organic disorder: Abnormal palpation of external genitals, testis, epididymis and spermatic cord; 5. Drug influence: use of any drug for PE, e.g. SSRI , PDE-5, tramadol, etc; 6. Known drug allergy to amide-type local anaesthetics or dapoxetine; 7. Currently participating, or in the past 30 days quit a another clinical research independent with this research; 8. Drugs, alcohol or substance abuse in last 6 months; 9. moderate or more severe erectile Dysfunction.

Design outcomes

Primary

MeasureTime frameDescription
Change of Intra-vaginal Ejaculation Latency Time(IELT)After enrollment,after 4 weeks' treatment,after 8 weeks' treatment,after 12 weeks' treatmentMost commonly used in research on premature ejaculation.
Change of score of Premature ejaculation diagnostic tool(PEDT)After enrollment,after 12 weeks' treatmentA questionnaire to evaluate and diagnose premature ejaculation
Change of grade Premature ejaculation profile(PEP)After enrollment,after 4 weeks' treatment,after 8 weeks' treatment,after 12 weeks' treatmentA questionnaire consists of 4 questions to evaluate the 4 aspects of the symptom of premature ejaculation
The change of results of Nerve electrophysiological examinationAfter enrollment,after 12 weeks' treatmentTo measure the penile sensory excitability and penile skin sympathetic excitability.
Clinical Global Impression of ChangeAfter 12 weeks' treatmentA single question to measure the change after treatment
Change of Chinese Index of Premature Ejaculation of five items(CIPE-5)After enrollment,after 12 weeks' treatmentA questionnaire to evaluate and diagnose premature ejaculation designed for Chinese people

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026